The Demand for Antiretroviral Drugs in the Illicit Marketplace: Implications for HIV Disease Management Among Vulnerable Populations

AIDS and Behavior

Volumn 19, Issue 5, 2015, Pages 857-868

  Tsuyuki, Kiyomi ^a   Surratt, Hilary L ^a   Levi Minzi, Maria A ^a   O’Grady, Catherine L ^a   Kurtz, Steven P ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Adherence; ARV; Diversion; HIV; Qualitative; Substance use

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; COMMERCIAL PHENOMENA; COMPLICATION; DISEASE MANAGEMENT; ECONOMICS; HIGH RISK BEHAVIOR; HIV INFECTIONS; HUMAN; INTERVIEW; MOTIVATION; MULTIVARIATE ANALYSIS; PRESCRIPTION; PSYCHOLOGY; QUALITATIVE RESEARCH; QUESTIONNAIRE; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; UNSAFE SEX; VULNERABLE POPULATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; COMMERCE; DISEASE MANAGEMENT; DRUG PRESCRIPTIONS; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; MOTIVATION; MULTIVARIATE ANALYSIS; QUALITATIVE RESEARCH; RISK-TAKING; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS; SURVEYS AND QUESTIONNAIRES; UNSAFE SEX; VULNERABLE POPULATIONS; YOUNG ADULT;

EID: 84939887331     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-014-0856-2     Document Type: Article

References (63)

1. Inciardi JA, Surratt HL, Kurtz SP, Burke JJ. The diversion of prescription drugs by health care workers in Cincinnati, Ohio. Subst Use Misuse. 2006;41(2):255–64.
2. Paulozzi L, Baldwin G, Franklin G, Kerlikowske RG, Jones CM, Ghiya N, et al. CDC grand rounds: prescription drug overdoses: a U.S. Epidemic. Centers for Disease Control (CDC), 2012 January 13, 2012. Report No.: Contract No.: 01.
3. Joranson DE, Gilson AM. A much needed window on opioid diversion. Pain Med. 2007;8(2):128–9.
4. Associated Press. AIDS drugs surface on the black market. New York Times. 1995.
5. Dorschner J. Activists: HIV care scam uses homeless. Miami Herald. 2005;30:2005.
6. Flaherty M, Gaul G. Florida Medicaid fraud costs millions, report says. Wash Post. 2003;19:2003.
7. Glasgow K. The new dealers: They’re poor, black, and HIV-positive. Their product? The AIDS medications intended to cure them. Miami New Times. 1999;21:1999.
8. Kurtz SP, Buttram ME, Surratt HL. Vulnerable infected populations and street markets for ARVs: Potential implications for PrEP rollout in the USA. AIDS Care. 2013:1–5.
9. Surratt HL, Kurtz SP. A national perspective on the abuse and diversion of prescription drugs. Nova Southeastern University Faculty Symposium; Nova Southeastern University2013.
10. Manhattan U.S. Attorney Announces Charges Against 48 Individuals in Massive Medicaid Fraud Scheme Involving the Diversion and Trafficking of Prescription Drugs. United States Department of Justice 2012.
11. Surratt HL, Kurtz SP, Cicero TJ, O’Grady C, Levi-Minzi MA. Antiretroviral medication diversion among HIV-positive substance abusers in South Florida. Am J Public Health. 2013;103(6):1026–8.
12. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–3.
13. Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother. 2005;55(4):413–6.
14. Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of prescription drug diversion among drug-involved club-and street-based populations. Pain Med. 2007;8(2):171–83.
15. Weathermon RA. Controlled substances diversion: who attempts it and how. US Pharmacist. 1999;24(12):32–47.
16. Grelotti DJ, Closson EF, Mimiaga MJ. Pretreatment antiretroviral exposure from recreational use. Lancet Infect Dis. 2013;13(1):10–2.
17. Grelotti DJ, Closson EF, Smit JA, Mabude Z, Matthews LT, Safren SA, et al. Whoonga: potential recreational use of HIV antiretroviral medication in South Africa. AIDS and behavior. 2013:1–8.
18. Davis GP, Surratt HL, Levin FR, Blanco C. Antiretroviral medication: An emerging category of prescription drug misuse. Am J Addict. 2013. doi:10.1111/j.1521-0391.2013.12107.x.
19. Liu AY, Kittredge PV, Vittinghoff E, Raymond HF, Ahrens K, Matheson T, et al. Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr (1999). 2008;47(2):241–7.
20. Mansergh G, Koblin BA, Colfax GN, McKirnan DJ, Flores SA, Hudson SM. Preefficacy use and sharing of antiretroviral medications to prevent sexually-transmitted HIV infection among US men who have sex with men. J Acquir Immune Defic Syndr (1999). 2010;55(2):e14–6.
21. Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr (1999). 2009;50(1):77–83.
22. Braunstein MS. Sampling a hidden population: noninstitutionalized drug users. AIDS Educ Prev. 1993;5(2):131–9.
23. Watters JK, Biernacki P. Targeted sampling: options for the study of hidden populations. Soc Probl. 1989;36(4):416–30.
24. Carlson RG, Wang J, Siegal HA, Falck RS, Guo J. An ethnographic approach to targeted sampling: problems and solutions in AIDS prevention research among injection drug and crack-cocaine users. Hum Org. 1994;53(3):279–86.
25. Coyle S. Women’s drug use and HIV risk: findings from NIDA’s cooperative agreement for community-based outreach/intervention research program. Women Health. 1998;27(1/2):1–18.
26. Miami Dade County Department of Health. Miami-Dade County Reported HIV (Not AIDS) Cases Through. 2012. http://www.dadehealth.org/downloads/2012%20HIV%20Reported.pdf. Accessed 29 Aug 2013
27. Charmaz K. Constructing grounded theory: a practical guide through qualitative analysis. Thousand Oaks: Sage Publications; 2006.
28. Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research. New York: Transaction Books; 2009.
29. Strauss AL. Qualitative analysis for social scientists. Cambridge: Cambridge University Press; 1987.
30. Strauss AL, Corbin J. Basics of qualitative research. Newbury Park: Sage publications; 1990.
31. National Alliance of State and Territorial AIDS Directors (NASTAD). ADAP Watch. Washington D.C.: National Alliance of State and Territorial AIDS Directors (NASTAD), 2011 September 9, 2011. Report No.
32. Quinn K, Skarbinski J. Health insurance coverage and type predict durable viral suppression among HIV+ adults in care: U.S. Medical Monitoring Project. 20th Conference on Retroviruses and Opportunistic Infections; March 3–6, 2013; Atlanta, GA2009.
33. Das-Douglas M, Riley ED, Ragland K, Guzman D, Clark R, Kushel MB, et al. Implementation of the Medicare Part D prescription drug benefit is associated with antiretroviral therapy interruptions. AIDS Behav. 2009;13(1):1–9.
34. Crowley JS, Kates J. Updating the Ryan white HIV/AIDS program for a new era: key issues & questions for the future: Henry J. Kaiser Family Foundation; 2013.
35. Mayer KH. Introduction: Linkage, engagement, and retention in HIV care: essential for optimal individual-and community-level outcomes in the era of highly active antiretroviral therapy. Clin Infect Dis. 2011;52(suppl 2):S205–7.
36. National Alliance of State and Territorial AIDS Directors (NASTAD). The ADAP Watch. 2013.
37. National Alliance of State and Territorial AIDS Directors (NASTAD). The ADAP Watch. 2012.
38. Schneider J, Kaplan SH, Greenfield S, Li W, Wilson IB. Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med. 2004;19(11):1096–103.
39. Roberts KJ. Physician-patient relationships, patient satisfaction, and antiretroviral medication adherence among HIV-infected adults attending a public health clinic. AIDS Patient Care and STDs. 2002;16(1):43–50.
40. Murphy DA, Roberts KJ, Martin DJ, Marelich W, Hoffman D. Barriers to antiretroviral adherence among HIV-infected adults. Aids patient care and STDs. 2000;14(1):47–58.
41. Mallinson RK, Rajabiun S, Coleman S. The provider role in client engagement in HIV care. AIDS Patient Care STDs. 2007;21(S1):S-77–S-84.
42. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.
43. Wong MD, Cunningham WE, Shapiro MF, Andersen RM, Cleary PD, Duan N, et al. Disparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patients. J Gen Intern Med. 2004;19(4):366–74.
44. WHO. HIV/AIDS treatment and care: clinical protocol for the WHO European Region. Copenhagen: World Health Organization, 2006.
45. Ding L, Landon BE, Wilson IB, Wong MD, Shapiro MF, Cleary PD. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med. 2005;165(6):618.
46. Westergaard RP, Ambrose BK, Mehta SH, Kirk GD. Provider and clinic-level correlates of deferring antiretroviral therapy for people who inject drugs: a survey of North American HIV providers. J Int AIDS Soc. 2012;15(1):10.
47. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr (1999). 2006;43(4):411.
48. Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11(2):185–94.
49. Shannon K, Kerr T, Lai C, Ishida T, Wood E, Montaner JS, et al. Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use. J Int Assoc Phys AIDS Care. 2005;4(3):66–72.
50. Liu H, Longshore D, Williams JK, Rivkin I, Loeb T, Warda US, et al. Substance abuse and medication adherence among HIV-positive women with histories of child sexual abuse. AIDS Behav. 2006;10(3):279–86.
51. Mehta SH, Kirk GD, Astemborski J, Galai N, Celentano DD. Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996–2008. Clin Infect Dis. 2010;50(12):1664–71.
52. Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996–2004. PLoS ONE. 2009;4(2):e4445.
53. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15(13):1707–15.
54. Giordano TP, Visnegarwala F, White AC Jr, Troisi CL, Frankowski RF, Hartman CM, et al. Patients referred to an urban HIV clinic frequently fail to establish care: factors predicting failure. AIDS Care. 2005;17(6):773–83.
55. Giordano TP, White CA Jr, Sajja P, Graviss EA, Arduino RC, Adu-Oppong A, et al. Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr. 2003;32(4):399–405.
56. Lopez E, Jones DL, Ishii M, Tobin JN, Weiss SM. HIV medication adherence and substance use: the smartest women’s project. Am J Infect Dis. 2007;3(4):240.
57. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O’Shaughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280(6):547–9.
58. Gardner LI, Holmberg SD, Moore J, Arnsten JH, Mayer KH, Rompalo A, et al. Use of highly active antiretroviral therapy in HIV-infected women: impact of HIV specialist care. J Acquir Immune Defic Syndr. 2002;29(1):69–75.
59. Landon BE, Wilson IB, McInnes K, Landrum MB, Hirschhorn LR, Marsden PV, et al. Physician specialization and the quality of care for human immunodeficiency virus infection. Arch Intern Med. 2005;165(10):1133.
60. Kitahata MM, Van Rompaey SE, Shields AW. Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;24(2):106–14.
61. Celentano DD, Lucas G. Optimizing treatment outcomes in HIV-infected patients with substance abuse issues. Clin Infect Dis. 2007;45(Suppl 4):S318–23.
62. Willenbring ML. Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches. AIDS. 2005;19:S227–S37.
63. Kates J, Garfield R, Young K, Quinn K, Frazier E, Skarbinsk J. Assessing the Impact of the Affordable Care Act on Health Insurance Coverage of People with HIV: Kaiser Family Foundation; 2014.